促动力药在管理系统性硬化症胃肠道受累中的作用:一项系统文献综述
该系统文献综述在PubMed和Embase系统检索促动力药对系统性硬化症(SSc)患者胃肠道功能和/或症状影响的研究,共纳入21项研究。甲氧氯普胺持续改善整体胃肠动力,西沙必利改善胃排空和结肠动力但不改善食管动力,奥曲肽改善小肠动力但延迟胃排空;仅普芦卡必利经经验证的患者问卷评估显示上、下消化道症状均改善。作者认为促动力药可能改善SSc患者胃肠动力和症状,未来需精心设计的研究以细化患者分层并优化治疗结局。
要点
- 甲氧氯普胺持续改善SSc患者整体胃肠动力,西沙必利改善胃排空和结肠动力但不改善食管动力。
- 奥曲肽改善小肠动力但延迟胃排空;仅普芦卡必利经经验证问卷评估显示上、下消化道症状均改善。
- 作者认为促动力药可能改善SSc患者胃肠动力和症状,未来需精心设计的研究以细化患者分层并优化治疗结局。
核心结论
- 促动力药可能改善SSc患者的胃肠动力和症状。
- 未来需要精心设计的研究以细化患者分层并优化治疗结局。
研究设计与样本
- 系统文献综述,在PubMed和Embase系统检索促动力药对SSc患者胃肠道功能和/或胃肠道症状影响的研究。
- 因研究设计、干预和结局预期存在广泛异质性,采用定性数据合成。
- 共纳入21项研究:13项聚焦胃肠道动力(采用客观检测),8项评估临床反应,6项两者兼评。
主要发现
- 甲氧氯普胺(7项研究)持续改善整体胃肠动力。
- 西沙必利(5项研究)改善胃排空和结肠动力,但不改善食管动力。
- 奥曲肽(4项研究)改善小肠动力但延迟胃排空。
- 仅普芦卡必利(1项研究)经经验证的患者问卷评估,显示上、下消化道症状均改善。
局限性
- 研究设计、干预和结局存在广泛异质性,因此采用定性数据合成。
- 作者指出未来需要精心设计的研究以细化患者分层并优化治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gastrointestinal involvement (GI) in SSc is frequent and heterogeneous, manifesting with different degrees of dysmotility. This systematic literature review aimed to summarize evidence on prokinetics for treating SSc-related GI dysmotility. METHODS: Studies investigating the effects of prokinetic agents on GI function and/or GI symptoms in patients with SSc were systematically identified on PubMed and Embase. A qualitative data synthesis was conducted, given the (anticipated) wide heterogeneity in study designs, interventions and outcomes. RESULTS: Twenty-one studies evaluating the effects of prokinetics in patients with SSc were included. Thirteen studies focused on GI motility using objective tests, eight assessed clinical responses, and six evaluated both. Cisapride (n = 5 studies), metoclopramide (n = 7 studies), octreotide (n = 4 studies) and prucalopride (n = 1 study) were among the most studied prokinetics, with varying effects on different GI anatomical regions. While metoclopramide consistently improved overall GI motility, other prokinetics provided selective benefits; cisapride improved gastric emptying and colonic motility, but not oesophageal motility, and octreotide improved small bowel motility but delayed gastric emptying. Regarding symptomatic improvement, only prucalopride was evaluated using a validated patient questionnaire, showing improvement in both upper and lower GI symptoms. CONCLUSION: Prokinetic drugs may improve GI motility and symptoms in patients with SSc. There is an unmet need for future well-designed studies to refine patient stratification and optimize treatment outcomes.
引用
- Ezquerra-Durán A, Alcala-Gonzalez LG, Guillen-Del-Castillo A, et al. The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review. Rheumatology (Oxford). 2025. PMID: 39909554. doi:10.1093/rheumatology/keaf064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。